THRESHOLD INITIATES PHASE I/II TRIAL EVALUATING GLUFOSFAMIDE AS FIRST-LINE PANCREATIC CANCER THERAPY

Threshold Pharmaceuticals has initiated patient enrollment for a Phase I/II clinical trial evaluating the dosing, safety and activity of Glufosfamide in combination with gemcitabine for treating advanced solid malignancies or as a first line treatment for pancreatic cancer.

Phase I of the Glufosfamide/gemcitabine study will evaluate various doses of Glufosfamide in combination with the standard dose of gemcitabine in patients with any kind of advanced solid malignancy for which gemcitabine is currently a treatment option. The Phase I portion of this study may enroll up to 15 patients. The maximum-tolerated dose combination determined in Phase I of the study will be used in the Phase II portion to treat patients with pancreatic cancer. Approximately 47 men and women with advanced pancreatic cancer will be enrolled in the Phase II clinical trial at various sites in the U.S. and Latin America.